Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

616461 TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem

TGF-β RI Kinase Inhibitor VI, SB431542, CAS 301836-41-9, is a cell-permeable inhibitor of SMAD2 phosphorylation. Inhibits the activity of ALK4 and ALK5 (IC₅₀ = 140 nM and 94 nM, respectively).

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide, Dihydrate, 4-[4-(1,3-Benzodioxol-5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide, Dihydrate, SB-431542

View Products on Sigmaaldrich.com
616461
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
301836-41-9C₂₂H₁₆N₄O₃. 2H₂O

Products

Catalogue NumberPackaging Qty/Pack
616461-5MGCN 5 mg
Description
OverviewA cell-permeable triarylimidazole compound that is shown to effectively inhibit cellular Smad2 phosphorylation (>90% inhibition by 10 µM inhibitor) upon vector-mediated expression of constitutively active ALK4, ALK5, or ALK7 in NIH 3T3 cells, while exhibiting little effect against Smad1 phosphorylation by other members of type I receptors for TGF-β in NIH 3T3 cultures expressing active ALK1, 2, 3, or 6. When tested directly in cell-free kinase assays, SB431542 is demonstrated to potently inhibit the activity of ALK4 and ALK5 (IC50 = 140 nM and 94 nM, respectively) with no or much reduced potency toward a panel of 24 other kinases (IC50 ≥10 µM in the presence of 10 µM ATP), including ALK2 and ALK6. Reported to improve the efficiency of 4-TF-induced human iPSCs generation from fibroblast cultures by >200-fold when used together with PD0325901 (Cat. No. 444966) and Thiazovivin (Cat. No. 420220). Also available as a 100 mM solution in DMSO (Cat. No. 616464).
Catalogue Number616461
Brand Family Calbiochem®
Synonyms4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide, Dihydrate, 4-[4-(1,3-Benzodioxol-5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide, Dihydrate, SB-431542
References
ReferencesIkushima, H., et al. 2009. Cell Stem Cell 5, 504.
Lin, T., et al. 2009. Nat. Methods 6, 805.
Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.
Product Information
CAS number301836-41-9
FormOff-white solid
Hill FormulaC₂₂H₁₆N₄O₃. 2H₂O
Chemical formulaC₂₂H₁₆N₄O₃. 2H₂O
Structure formula ImageStructure formula Image
Quality LevelMQ300
Applications
Biological Information
Purity≥97% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
616461-5MGCN 04055977185928

Documentation

TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

TGF-β RI Kinase Inhibitor VI, SB431542 - CAS 301836-41-9 - Calbiochem Certificates of Analysis

TitleLot Number
616461

References

Reference overview
Ikushima, H., et al. 2009. Cell Stem Cell 5, 504.
Lin, T., et al. 2009. Nat. Methods 6, 805.
Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision30-August-2010 RFH
Synonyms4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide, Dihydrate, 4-[4-(1,3-Benzodioxol-5-yl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide, Dihydrate, SB-431542
DescriptionA cell-permeable triarylimidazole compound that is shown to effectively inhibit cellular Smad2 phosphorylation (>90% inhibition by 10 µM inhibitor) upon vector-mediated expression of constitutively active ALK4, ALK5, or ALK7 in NIH 3T3 cells, while exhibiting little effect against Smad1 phosphorylation by other members of type I receptors for TGF-β in NIH 3T3 cultures expressing active ALK1, 2, 3, or 6. When tested directly in cell-free kinase assays, SB431542 is demonstrated to potently inhibit the activity of ALK4 and ALK5 (IC50 = 140 nM and 94 nM, respectively) with no or much reduced potency toward a panel of 24 other kinases (IC50 ≥10 µM in the presence of 10 µM ATP), including ALK2 and ALK6. Reported to improve the efficiency of 4-TF-induced human iPSCs generation from fibroblast cultures by >200-fold when used together with PD0325901 (Cat. No. 444966) and Thiazovivin (Cat. No. 420220).
FormOff-white solid
Intert gas (Yes/No) Packaged under inert gas
CAS number301836-41-9
Chemical formulaC₂₂H₁₆N₄O₃. 2H₂O
Structure formulaStructure formula
Purity≥97% by HPLC
SolubilityDMSO (100 mg/ml) or Ethanol (10 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesIkushima, H., et al. 2009. Cell Stem Cell 5, 504.
Lin, T., et al. 2009. Nat. Methods 6, 805.
Maherali, N. and Hochedlinger, K., 2009. Curr. Biol. 19, 1718.
Callahan, J.F., et al. 2002. J. Med. Chem. 45, 999.
Inman, G.J., et al. 2002. Mol. Pharmacol. 62, 65.
Laping, N.J., et al. 2002. Mol. Pharmacol. 62, 58.